The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide

Journal of Human Hypertension

Volumn 13, Issue 10, 1999, Pages 683-687

  Raskin, P ^a   Guthrie, R ^b   Flack, J M ^c   Reeves, R A ^d   Saini, Ravi ^d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c HARPER UNIVERSITY HOSPITAL   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

Author keywords

Angiotensin II receptor antagonist; Combination therapy; Diuretic; Hydrochlorothiazide; Irbesartan

Indexed keywords

HYDROCHLOROTHIAZIDE; IRBESARTAN; LIVER ENZYME; PLACEBO;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; TITRIMETRY; VERTIGO;

EID: 0032873967     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000888     Document Type: Article

References (14)

1. Kaplan NM. Implications for cost-effectiveness. Combination therapy for systemic hypertension. Am J Cardiol 1995; 76: 595-597.
2. Waeber B, Brunner HR. Main objectives and new aspects of combination treatment of hypertension. J Hypertens 1995; 13 (Suppl 2): S15-S19.
3. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-2446.
4. 1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther 1993; 265; 826-834.
5. Timmermans PBMWM et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45: 205-251.
6. Pool JL et al. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens 1998; 11: 462-470.
7. Reeves RA, Lin C-S, Kassler-Taub K, Pouleur H. Dose-related efficacy of irbesartan for hypertension: an integrated analysis. Hypertension 1998; 31: 1311-1316.
8. Simon TA et al. Safety of irbesartan in the treatment of mild to moderate systemic hypertension. Am J Cardiol 1998; 82: 179-182.
9. Marino MR et al. Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of the angiotensin II blocker irbesartan. Clin Drug Invest 1997; 14: 383-391.
10. Kochar M et al. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens 1999; 12: (in press).
11. Phillips P et al. Antihypertensive efficacy of the combination of irbesartan and hydrochlorothiazide assessed by 24-hour ambulatory blood pressure monitoring [abstract]. J Hypertens 1997; 15 (Suppl 4): S181.
12. Rosenstock J et al. The effects of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients non-responsive to hydrochlorothiazide alone. J Clin Pharm Ther 1998; 23: 433-440.
13. McVeigh GE, Flack J, Grimm R. Goals of antihypertensive therapy. Drugs 1995; 49: 161-175.
14. McCombs JS, Nichol MB, Newman CM, Sclar DA. The costs of interrupting antihypertensive drug therapy in a Medicaid population. Med Care 1994; 32: 214-226.